NEWS

  • AACR Annual Meeting MPN Highlights

    While the Annual Meeting of the American Association for Cancer Research (AACR), held in April 2023, focused a great deal on understanding, decoding, and advocating for cancer health equity and inclusion, there were also significant scientific take-aways important to the treatment of MPNs.  One presentation by Haris Ali, MD, City of Hope Comprehensive Cancer Center,… Read More »AACR Annual Meeting MPN Highlights

    READ MORE

    Preventing Blood Clots in MPNs

    Advancing Research: Preventing Blood Clots in MPNs Blood clots, heart attacks, and strokes are leading causes of death or disability in patients with MPNs, typically as a result of elevated platelets and/or red blood cells. Dr. Joan Beckman’s lab at the University of Minnesota is currently working to determine whether growth-arrest-specific 6 protein (Gas6) contributes… Read More »Preventing Blood Clots in MPNs

    READ MORE

    Today’s Understanding of MPNs: Review Articles in ASH Journal Blood

    Today’s Understanding of MPNs: Article Reviews in ASH Journal Blood The world’s current understanding of myeloproliferative neoplasms (MPNs) is showcased in a review of MPN articles published in the April 2023 issue of the American Society of Hematology (ASH) journal Blood (Vol 141 Number 16: April 20, 2023).  The articles describe the latest advances in the field… Read More »Today’s Understanding of MPNs: Review Articles in ASH Journal Blood

    READ MORE

    An Important Moment in the Treatment of MPNs

    An Important Time for MPNs “This is a profoundly important moment in the treatment of MPNs,” according to Raajit Rampal, MD, PhD, a hematology/oncology specialist at Memorial Sloan Kettering, and MPNRF’s medical advisor. We now have three FDA-approved JAK inhibitors – ruxolitinib, pacritinib, and fedratinib. We have combinations to offer, including a number of new… Read More »An Important Moment in the Treatment of MPNs

    READ MORE

    Nanobody-Based Targeted Therapy

    MPNRF ADVANCING RESEARCH: Nanobody-Based Targeted Therapy Through a 2022 MPNRF Thrive Initiative award, Najla Arshad, PhD, Yale University School of Medicine, will explore Development of Nanobody-Based Targeted Therapy for Myeloproliferative Neoplasm, with funding for up to two years.  “There is a real need for a therapy that can target and eliminate these diseased cells, to… Read More »Nanobody-Based Targeted Therapy

    READ MORE

    Thrive Initiative Press Release

    MPN Research Foundation Awards Additional $1.8 Million for Blood Cancer Research into Myeloproliferative Neoplasms Dec. 14, 2022 (Chicago) − MPN Research Foundation (MPNRF) announces its 2022 Thrive Initiative recipients for projects that fill research funding gaps, some of which surfaced due to the pandemic. This $1.8 million in awards is in addition to currently funded… Read More »Thrive Initiative Press Release

    READ MORE

    Richard T. Silver, MD

    Before he helped define criteria for the diagnosis of polycythemia vera (PV) and introduced interferon to treat it; before he chaired the guidelines committee for the treatment of chronic myeloid leukemia (CML) for the American Society of Hematology; and long before his name branded an internationally recognized clinic that specializes in myeloproliferative neoplasms (MPNs); Richard… Read More »Richard T. Silver, MD

    READ MORE

    30 FACTS about MPNs

    Our investments in global, cutting edge, multi-center MPN research have directly advanced knowledge about the causes of these rare, chronic blood cancers, leading to the development of more and better treatments and improved quality of life for people living with an MPN. Clinical trials are an integral part of this process. 30 FACTS ABOUT MPN… Read More »30 FACTS about MPNs

    READ MORE

    Advances of Note From EHA2022 

    The European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners, and other participants in June to share the latest advances in hematology. Among those on MPNs were the following:   “ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFa axis mediated inflammation and fibrocyte generation in myeloproliferative neoplasms”   This study illustrated the crucial role… Read More »Advances of Note From EHA2022 

    READ MORE

    MPN Stem Cells Suffer From ‘Corrupting Influence’

    Interferon has been shown to be very effective in some patients with MPNs, often alleviating their fatigue, enlarged spleen, and other symptoms. Some patients show important additional benefits, such as molecular response, even long-term remission and the delay of disease progression. For others with ET, PV or MF, interferon has no measurable effect. As part… Read More »MPN Stem Cells Suffer From ‘Corrupting Influence’

    READ MORE

    1 2 3 40
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?